A New, Young, and Hopeful Monkey

Hey WSO,

Just wanted to introduce myself to what seems like a great site and a fantastic resource. I'm going into my sophomore year at the University of Pennsylvania, studying in the Vagelos dual-degree program in Life Sciences & Management (degrees from Wharton and the College of Arts and Sciences). I'm planning on concentrating in Finance and Healthcare Management in Wharton, with a Biology major in the college. My interests lie in the interface of business and science--specifically, I'm really looking to explore the pharmaceutical industry, healthcare consulting, and investing in the biotech/pharma/healthcare realm. I'd definitely love some advice from anyone with expertise in the field!

Looking forward to years of monkeying around.

 

Thanks for the words of encouragement! I'm really excited to see where the industry is headed; seems like the sky is the limit.

"True humility is not thinking less of yourself; it is thinking of yourself less."
 

not a biotech analyst, nor do I have expertise, I know a little about the business because many of my friends are in the industry and many of my clients are as well. Here's my advice: learn the different areas of pharma like medical device, big pharma (MRK, PFE), bioscience like boston scientific, biogen, etc., contract research, health insurance, etc.

I say this because medical device companies are widget makers, with more predictable earnings, whereas a company like a biogen might lose money for years developing a molecule but then hit a payday when Merck buys it, so it's important to know the relevant metrics as a drug goes through development but has not yet become marketable.

 

Thanks for the advice! I completely agree. I've been doing a lot of work with clinical strategy here, which has really allowed me to see the whole process of drug development from a different perspective. And from what I understand, understanding the ups and downs of drug development and the way drug development works--the way the company works, essentially--is the key to understanding the company's value and potential. I'm looking to do some personal investing in biotech, so I've been navigating Cowen biotech and therapeutic reports to see some of their analyses. It's great stuff, and I'm always looking to learn more!

"True humility is not thinking less of yourself; it is thinking of yourself less."
 

Saepe odit quos sed enim ad tempora. Sit voluptatem perspiciatis magnam sunt voluptatibus sequi. Eos quis quasi voluptate eveniet molestias molestiae et. Facilis explicabo minus voluptatibus adipisci incidunt. Fugit sit illo eos qui.

Animi delectus ipsa ut illum aperiam est consequatur ut. Beatae doloribus ipsam aut nihil. Illum totam exercitationem fugit nesciunt dolorum temporibus.

"True humility is not thinking less of yourself; it is thinking of yourself less."

Career Advancement Opportunities

June 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Perella Weinberg Partners New 98.9%
  • Lazard Freres 01 98.3%
  • Harris Williams & Co. 24 97.7%
  • Goldman Sachs 17 97.1%

Overall Employee Satisfaction

June 2024 Investment Banking

  • Harris Williams & Co. 19 99.4%
  • JPMorgan Chase 10 98.9%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 05 97.7%
  • Moelis & Company 01 97.1%

Professional Growth Opportunities

June 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.9%
  • Perella Weinberg Partners 18 98.3%
  • Goldman Sachs 16 97.7%
  • Moelis & Company 05 97.1%

Total Avg Compensation

June 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (22) $375
  • Associates (93) $259
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (69) $168
  • 1st Year Analyst (206) $159
  • Intern/Summer Analyst (149) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”